Labels After reconstitution, label your vial with the date, the concentration (mg/mL), and the contents
Two other companies applied before April of 2024, when Health Canada updated its policies to identify companies with submissions under review
placebo) 5 Consistent with the types of adverse events seen in clinical trials for other incretins, the most common adverse events among participants treated with retatrutide (9 mg and 12 mg, respectively) were nausea (38.1% and 43.2%) vs
Practical considerations for researchers For researchers interested in retatrutide specifically, or in the broader field of incretin-based pharmacology, several practical considerations apply
Seek immediate medical attention for severe dizziness with loss of consciousness, chest pain, neurological symptoms, or severe abdominal pain
J Nephropathol